Absci Corporation Common Stock (ABSI) is a publicly traded Healthcare sector company. As of May 21, 2026, ABSI trades at $4.94 with a market cap of $770.95M and a P/E ratio of -5.93. ABSI moved +6.70% today. Year to date, ABSI is +32.35%; over the trailing twelve months it is +77.42%. Its 52-week range spans $2.01 to $6.72. Analyst consensus is strong buy with an average price target of $8.52. Rallies surfaces ABSI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Absci Q1 Revenue Falls 83% to $0.2M as ABS-201 Trial Progresses: Absci dosed four SAD cohorts in its Phase 1/2a HEADLINE trial for ABS-201, with safety and PK data supporting two-to-three injections over six months and MAD dosing in alopecia patients. The company added anti-PRLR ABS-202 to its pipeline and saw Q1 revenue drop to $0.2 million from $1.2 million.
| Metric | Value |
|---|---|
| Price | $4.94 |
| Market Cap | $770.95M |
| P/E Ratio | -5.93 |
| EPS | $-0.82 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.72 |
| 52-Week Low | $2.01 |
| Volume | 3.17M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.84M |
| Net Income | $-118.44M |
| Gross Margin | 0.00% |
7 analysts cover ABSI: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.52.